Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@unityhealth.to
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
| Sponsor Type | Funding Program Title | Amount and Duration | Description | Deadline | |
|---|---|---|---|---|---|
| Tri-Agency | CIHR Team Grant: Healthy Youth (2024) | Up to $300,000 per year for up to 5 years. | The purpose of this funding opportunity is to support research teams that bring evidence to at least two of the six youth-identified priorities of Canada’s Youth Policy to inform meaningful change that improves youth health and well-being. The six priority areas are: Leadership and Impact; Health and Wellness; Innovation, Skills and Learning; Employment; Truth and Reconciliation; Environment and Climate Action. | Registration: December 10, 2024; Application: February 4, 2025. | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Moving Upstream - Structural Determinants of Health Catalyst Grants | Up to $125,000 for one year. | This funding opportunity will support interdisciplinary research to analyze, contextualize and/or evaluate how structural drivers can create, maintain, or exacerbate health (in) equity and population health across sub-groups, regions, contexts and settings. The desired outcome is to contribute to the evidence base in Canada on the structural drivers that improve, sustain, or deteriorate population health and health equity. | Anticipated Deadlines: Registration: Fall 2024. Application: Fall 2024. | |
| Tri-Agency | CIHR Catalyst Grant: Digital Health | Up to $250,000 per year for up to 4 years | This funding opportunity will catalyze discovery in digital health, advance pivotal research, and inform applications or interventions relevant to CIHR- Institute of Musculoskeletal Health and Arthritis (IMHA)’s broad mandate areas. CIHR-IMHA will invest in digital health research that has the potential for immediate-to-medium term health impact (2-10 years). | December 3, 2024. | |
| Tri-Agency | CIHR Operating Grant Pandemic Research Platforms Interim Funding | Up to $1.0M or 1.5M per year for up to 2 years, depending on research area. | This funding opportunity aims to prevent the loss of key pandemic and public health emergency infrastructure by supporting existing research platforms and enabling rapid activation of said platforms in emergency scenarios, such that critical research evidence for Canada’s ongoing pandemic response needs will continue to be available. The research platform must be in alignment with with ALL four objectives of this funding opportunity and with at least one relevant research area. | LOI: December 5, 2024. Full Application (by invitation): February 4, 2024. | |
| Tri-Agency | CIHR Call for Proposals: Evaluating Canadian Biotech with RCTs | Up to CAD $400,000. | Canadian biotechnology and clinical trial communities rarely intersect, and consequently few Canadian researchers undertake randomized controlled trials (RCTs) evaluating Canadian biotechnologies. Since most biotechnologies require RCTs demonstrating efficacy and safety to obtain regulatory approvals in Canada, the objective of this opportunity is to fund trials evaluating products from Canadian-controlled biotechnology companies in partnership with Accelerating Clinical Trials (ACT) Network clinical trialists. Applicants can request funds to facilitate phase 2, pilot, or Vanguard trials. Trials that assess safety, recruitment potential, and feasibility are also welcome provided they are an RCT. The nominated principal investigator has to be Canadian researcher who is a member of an ACT Network. | December 20, 2024. | |
| Tri-Agency | CIHR: Travel Awards | Up to CAD $5,000. | Through the Institute Community Support (ICS) Program, the CIHR Institutes and Initiatives are launching the ICS Travel Awards competition for students, postdoctoral fellows, early career researchers and knowledge users to present their own research at national and international meetings, workshops, and/or conferences. | January 7, 2025. | |
| Tri-Agency | CIHR Other: CIHR-IMHA Inclusive Research Excellence Prizes | $25,000 research grant funds. | The CIHR-IMHA Inclusive Research Excellence prizes are designed to recognize completed research projects under the broad IMHA mandate areas that have demonstrated a strong commitment to one of six (6) cross-cutting concepts covered under research domains / pools. Prizes will be awarded for completed research projects in the following six pools: Indigenous Health Research; Open Science; Research Impact; Team Science; Patient Engagement; Implementation Science. Please note that some pools focus on approaches / methods / impacts rather than a specific research area, and therefore, may receive applications conducting projects from a variety of areas falling under the broad IMHA mandate areas. | Registration: January 23, 2025. Application: February 19, 2025. | |
| Tri-Agency | SSHRC Destination Horizon Grants | Up to $15,000 for 1 year | This supports researchers to build capacity, foster existing partnerships, and further develop networks and/or consortia with European Union and other “associated countries” researchers, with the ultimate goal of applying to Horizon Europe—Pillar II calls for proposals. Destination Horizon Grants proposals are expected to respond to the objectives of the Research Partnerships program. The grants are not intended to support implementation of Horizon Europe projects. | January 22, 2205; May 22, 2025; September 22, 2025. | |
| Tri-Agency | CIHR Operating Grant: Research on Research Joint Initiative | Up to $200,000 for up to 3 years. | Research on research, also known as meta-research, is the application of rigorous methods and analysis to the practice of research itself – its methods, standards, and evaluation. The three Canadian core partners of the Research on Research Institute (RoRI) (SSHRC, CIHR, and Michael Smith Health Research BC), have joined together to launch this joint initiative as part of ongoing efforts to support meta-research in the Canadian context. The overall goal of this joint initiative is to enhance national capacity for meta-research and to bring Canadian expertise and perspectives into the international dialogue on improving research funding practices | February 20, 2025. | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Bringing Biology to Cancer Prevention Team Grants | Up to CAD $400,000 per year for up to 5 years. | These grants aim to unite interdisciplinary research teams to advance the biological and mechanistic understanding of cancer etiology, genesis, and risk, linked with host, lifestyle, environmental, social, and other factors, to identify new targets and approaches for cancer prevention, risk reduction, and early detection. Collaborations between traditional cancer prevention researchers (e.g., population and public health researchers, epidemiologists, social scientists) and those from other disciplines (e.g., biologists, immunologists, geneticists, drug developers) or who are new to the field are strongly encouraged. Collectively, these research teams will develop and disseminate evidence-based solutions to enable improvements in cancer prevention, risk reduction, and early detection at the individual and/or population-level. | Anticipated Timelines: Webinar: Winter 2025 Launch: Fall 2024 / Winter 2025 Registration Deadline: Winter 2025 Application Deadline: Summer 2025 *These timelines are estimates and subject to change. | |
| Tri-Agency | NSERC Alliance Grants | $20,000 to $1 million per year for 1-5 years | Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Tri-Agency | NSERC Alliance International | Collaboration Grants: Up to $100,000 per year for up to 3 years. | These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector ad to establish and grow international research collaborations and projects that have a high potential for impact in NSE disiplines. | No Deadline | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Community Based Research in Climate Change Priority Areas | Up to $125,000 for one year. | The purpose of this funding opportunity is to support the partnered work of communities and researchers in knowledge development and capacity-building initiatives of relevance to communities working to combat the differential health impacts of climate change. This will support activities relevant to one of the following research areas: Climate Justice; Alternative Diagnoses of Lyme Disease; Food Security in Northern Communities; and Health Impacts of Climate Change on Older Adults. | Anticipated Deadlines: Registration: Late summer 2024. Application: Fall 2024. | |
| Other Canadian | Canadian Hemophilia Society (CHS): Dream of a Cure Research Program: | Up to $150,000 over 2 or 3 years | This supports research focused on improving the health and the quality of life of all people with inherited bleeding disorders and finding a cure. | November 29, 2024. | |
| Other Canadian | Canadian Hemophilia Society (CHS): CHS/Pfizer Care until Cure Research Program: | Up to $150,000 over 2 or 3 years | This supports research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder. | November 29, 2024. | |
| Other Canadian | Canadian Hemophilia Society (CHS): CHS – Bayer – ADVANCE Canada Research Program: | $45,000 for one year. | The research program will support studies that will identify and provide insight into key issues associated with the ageing hemophilia population; identify how management of age-related co-morbidities should be adapted to those with hemophilia; or generate and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia. | November 29, 2024. | |
| Other Canadian | Veterans Affairs Canada (VAC): Evaluating Trauma-Informed Support for Military Personnel and Enhancing Access to Resources using AI: | $40,000.00 | This seeks proposals to evaluate the feasibility and effectiveness of using of LLM-based chatbots for trauma-informed support for sexual assault survivors in the military. | November 29, 2024. | |
| Other Canadian | Veterans Affairs Canada (VAC): Measurement-based care (MBC) in military and veteran mental health care systems | $250,000 for 18 months. | This seeks submissions to conduct a review and synthesis of the academic literature and public documents regarding emerging trends, current and best practices and challenges in MBC in military, veteran, and civilian mental healthcare systems across the Five Eyes nations (Australia, Canada, New Zealand, United Kingdom, and United States). | November 29, 2024. | |
| Other Canadian | Sigma/Canadian Nurses Foundation Grant | Up to USD $5,000. | This supports research that advances the practice of nursing with an emphasis on nursing care issues. Nursing care research or clinical nursing research is defined as research that is practice-based or that will provide the groundwork for future practice-based research studies. Research funded through this grant must provide evidence that there is a potential impact on nursing practice, whether direct or indirect. | December 1, 2024. | |
| Other Canadian | Brain Canada: 2024 Future Leaders in Canadian Brain Research | CAD $100,000 for 2 years | The purpose of this program is to accelerate novel and transformative research that will fundamentally change our understanding of nervous system function and dysfunction and their impact on health. The ultimate goal is to reduce the social and economic burden of neurological and mental illnesses through prevention, early diagnosis, and treatment. Open to early-career investigators within seven years* of starting their first independent research position. *Brain Canada is implementing an extended eligibility window, in line with federal granting agencies, to account for delays to research caused by the COVID-19 pandemic. | LOI: December 2, 2024. Full application: March 14, 2025. | |
| Other Canadian | Centre for Aging + Brain Health Innovation (CABHI): Ignite Program | Non-dilutive funding in the range of $50,000 to $150,000. | CABHI supports innovations that address challenges associated with older persons and their care partners, including Aging at Home, Caregiver Support, Care Coordination and Navigation, Cognitive and Mental Health, Financial Health and Wellness. The Ignite program is designed to target the challenges faced by early-stage innovators. In addition to funding, successful applicants will gain access to CABHI’s Acceleration Services. | December 2, 2024. | |
| Other Canadian | Ontario Institute for Cancer Research (OICR) Clinical Translation Pathway: Innovation to Implementation (I2I) Funding Competition | Up to $100,000 total costs for up to 2 years. | OICR seeks to bridge the gaps between research products and their use in real-world settings by facilitating behaviour or system changes. The goal of this program is to fund research activities to study ways to speed up the appropriate adoption of innovations. Projects that are in-scope include those aimed at: facilitating the adoption of research output, interventions, policies, or practices; evaluating the comparative effectiveness and cost effectiveness of different implementation strategies; developing and testing implementation science methods or strategies; investigating the barriers to implementation or developing optimal solutions to implementation challenge. | LOI: December 5, 2024. Full Application (by invitation): April 10, 2025 | |
| Other Canadian | U of T / SickKids Edwin S.H. Leong Centre for Healthy Children 2024 Catalyst Grant Competition | Up to $75,000 for up to 2 years. Priority given to 1-year projects. | This seeks to support research in response to child and family health needs with the potential to translate into practice, and eventually into public policy. Where evidence-based interventions already exist, the fund seeks to support social policy research that mitigates the impacts of structural and social determinants of health. A preference will be given to the following areas: Pilot initiatives for health equity; Intersectoral approaches; Policy research. | LOI: December 6, 2024. Full Application: February 14, 2025 | |
| Other Canadian | Breakthrough T1D: Common Mechanisms in Autoimunity Insight Awards | Up to $150,000 for for 1 year. | The purpose of the Common Mechanisms in Autoimmunity Insight Awards is to establish proof-of-concept research toward the collaborative advancement of innovative ideas and therapeutic approaches that address needs and knowledge gaps across multiple autoimmune diseases. All project proposals should be relevant to multiple autoimmune diseases, two of which should be relevant to multiple sclerosis, systemic lupus erythematosus (or one of its manifestations), and/or type 1 diabetes. | January 9, 2025 | |
| Other Canadian | Canadian Anesthesiologists' Society (CAS): Career Scientist Award | $60,000 over 2 years. | Provides partial salary support over two years to a qualified new investigator to fund a minimum of two days per week of protected research time. The award requires availability of matching funds from the successful applicant's university or faculty. | January 10, 2025. | |
| Other Canadian | Canadian Anesthesiologists' Society (CAS): New Investigator Operating Grant: | Up to $30,000 over 2 years. | For applicants who commenced independent practice or received their first faculty appointment within five years of the application deadline. | January 10, 2025. | |
| Other Canadian | Canadian Anesthesiologists' Society (CAS): Open Operating Grant | Up to $30,000. | An applicant may be at any stage of their career development but must hold a faculty appointment at a Canadian medical school. | January 10, 2025. | |
| Other Canadian | Canadian Anesthesiologists' Society (CAS): Section Operating Grants | Range from up to $10,000-$30,000. | Individuals are eligible to apply for Section Grants if they are a current member of the Section offering the award and the proposed research is directly related to the Section’s goals and objectives. | January 10, 2025. | |
| Other Canadian | Emerging and Pandemic Infections Consortium (EPIC): Future Leaders Prizes | $5,000 | This celebrates the best and brightest PhD students who graduate each year from among the EPIC research community. These competitive prizes identify the top graduate in each of four streams: applied and/or translational research; clinical research; fundamental research; or population, global and public health research | January 15, 2025. | |
| Other Canadian | Heart & Stroke Foundation of Canada: International Research Challenge on Women’s Cardiovascular Health | Up to USD $10 million for 5 years | This invites researchers to compete in a new research challenge that aims to transform the landscape of women’s cardiovascular health. | January 15, 2025. | |
| Other Canadian | TRANSFORM HF: Collaboration Starter Grants (CSG) | Up to CAD $10,000. | This opportunity aims to encourage and support TRANSFORM HF members in forming collaborations with new partners – either within or outside the TRANSFORM HF network – on early-stage projects that advance our mission of advancing equitable access to high quality heart failure care through digital innovation. Three types of supports are available: 1) proposal development meetings, collaborative project activities, patient or Knowledge Keeper compensation and facilitation; 2) scoping and preliminary project research and data collection; 3) research proposal writing and editing. Priority will be given to project proposals that were initiated during a TRANSFORM HF network meeting, that expand the network and its reach, and that are led by applicants who have not received previous CSG funding. | January 17, 2025. | |
| Other Canadian | Health Canada Youth Mental Health Fund | Up to $500,000 per year for up to 3 years | This funding program aims to to improve the mental health of youth and for their families, and to enhance availability, accessibility and quality of mental health supports and services for youth, with a particular focus on equity-deserving and underserved groups. | January 22, 2025. | |
| Other Canadian | Ontario HIV Treatment Network (OHTN): Winston Husbands Leadership Award in Strengthening the Response to HIV among Black Communities | Up to $150,000 for up to 2 years. | This provides salary support for emergent leaders who are interested in working closely and collaboratively with the OHTN to drive change, contribute to rapid learning and improvement in our sector, and build HIV innovation capacity in Ontario. Eligible applicants include scholars, researchers, physicians, service providers, knowledge users, or policy makers who are affiliated with a university or research institution in Ontario as postdoctoral fellows or junior faculty with a tenure stream appointment at the time of application and duration of the award. | January 22, 2025. | |
| Other Canadian | Marathon of Hope Cancer Centers Network (MOHCNN): Health Informatics & Data Science Awards | $40,000 for 1 year | To provide outstanding young researchers in health informatics and related fields with funding to support high-quality research in precision oncology. . Please see the funding opportunity website for full eligibility criteria | January 26, 2025. | |
| Other Canadian | Lung Cancer Canada: Give a Breath Research Award | Up to CAD $25,000. | This award is designed to address critical gaps in the understanding and treatment of advanced lung cancer, specifically focusing on post-first-line therapy options. The research focus of applications should revolve around advancements for patients with advanced or metastatic (i.e., stage III or IV) lung cancer; specifically, initiatives that apply to those beyond first-line therapy. Proposals with direct practical relevance to Canadians with lung cancer will be prioritized. Applications are encouraged from, but not limited to, the areas of biomedical, clinical, health services, social, and population health research. | January 31, 2025. | |
| Other Canadian | Marathon of Hope Cancer Centers Network (MOHCNN): Training Program- Clinician Scientist Awards | $75,000/year for 3 years | This provides outstanding young clinician investigators with funding to support high quality research in precision oncology. Please see the funding opportunity website for full eligibility criteria | February 2, 2025. | |
| Other Canadian | Lung Cancer Canada: Lung Ambition Awards | Up to $50,000 | This grant program is open to all Canadian clinicians and researchers (across the multi-disciplinary spectrum) who work in the lung cancer space. It supports research in lung cancer within the following areas: • Enhancing early detection – including research into methodologies like screening, incidental pulmonary nodules and blood-based testing, particularly for those individuals not meeting current screening criteria • Improving the timeliness and/or coordination of care – including ways in which institutions or health care systems can improve care along the patient pathway • Addressing disparities to improve equity – including identification of systemic barriers and ways to overcome them | February 7, 2025. | |
| Other Canadian | Kidney Foundation of Canada: KRESCENT Program-New Investigator Award | $70,000 (MD or equivalent degree) or $65,000 (Ph.D. without a MD or equivlanet degree) for up to 3 years. | Provides salary support to individuals who have clearly demonstrated excellence during their pre-doctoral and post-doctoral training in kidney disease. Applicants must be within the first three years of their first faculty appointment (Assistant Professor level or equivalent) at the time the Award commences, hold an MD and/or PhD, including Allied Health professionals. | March 3, 2025. | |
| Other Canadian | Heart & Stroke Foundation of Canada: Personnel Awards for Black Scholars | CAD $40,000/year for up 3 years (PhD); CAD $27,000/year for up 2 years (MSc). | These awards aim to promote strategic growth in heart and brain health science with Black communities by supporting Black students pursue their post graduate studies. | March 20, 2025. | |
| Other Canadian | Heart & Stroke Foundation of Canada: Personnel Awards for Indigenous Scholars | CAD $40,000/year for up 3 years (PhD); CAD $27,000/year for up 2 years (MSc). | These awards aim to promote strategic growth in heart and brain health science with Indigenous communities by supporting Indigenous students pursue their post graduate studies | March 20, 2025. | |
| Other Canadian | U of T Emerging and Pandemic Infections Consortium (EPIC): Researcher Mobility Awards | $4,000 for North American host institutions/sites; $6,000 for host institutions/sites in other countries. | Support high-calibre doctoral students or postdoctoral fellows to develop new skillsets and strengthen global linkages by providing financial support for them to undertake research training or complete collaborative field work outside of Toronto. | Rolling basis until May 31, 2025. | |
| Other Canadian | Multiple Sclerosis Society of Canada: Contract Research Organization (CRO) Grant | Up to $100,000 to pay for CRO services for up to a 1 year term. | This will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS. | Open competition with no set deadline. | |
| Other Canadian | Grand Challenges Canada: Transition To Scale (TTS) Request for Proposals | Range from $250,000 to $3M for 6 months up to 2 years | This seeks to support the transition to scale and sustainability of Bold Ideas with Big Impact in Global Health. Applications are invited in the following areas: Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options. | Concept notes accepted on a rolling basis | |
| Other Canadian | University of Toronto Institutional Strategic Initiatives (ISI) | From $50,000-$300,000 per year for up to 3 years. | ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. | Ongoing | |
| Other Canadian | Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs | -- | The NRC offers potential opportunities for collaboration in the following areas: Aging in Place, Artificial Intelligence for Design, Disruptive Technology Solutions for Cell and Gene Therapy, High-throughput and Secure Networks, and Pandemic Response. | Ongoing | |
| Other Canadian | Rare Diseases: Models & Mechanisms Network Catalyst Grants | $25,000 | Catalyst Grants fund projects that will allow rapid confirmation of potentially disease-causing genes, and fuel pilot studies to improve understanding of how specific gene mutations cause disease. This application is intended for investigators who wish to link their gene discovery to a model organism researcher. | Continuous | |
| Other Canadian | Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant | Health Research Grant: Up to $250,000 for 3 years. New Investigator Grant: Up to $300,000 for 3 years. | Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. | Rolling deadline | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Leveraging Grant | Up t0 $80,000 | To enable researchers, with non-AGRI funding to augment projects with a gambling-related component. | Rolling call | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Team Development Grants | Up to $10,000 for up to 18 months | To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs. | Rolling call | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Small Grants | Up to $10,000 for up to 1 year | To support small developmental initiatives typically intended to lead to major grant applications. | October 1st and May 1st each year | |
| Other Canadian | Telus Funds | Various | For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition. | Various | |
| Other Canadian | Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program | Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.) | This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. If you are interested, please contact Samar Saneinejad at Samar.Saneinejad@unityhealth.to | No Deadline | |
| Other Canadian | Multiple Sclerosis Society of Canada: Contract Research Organization (CRO) Grant | Up to $100,000 for 1 year | The CRO Grant will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS. The CRO does not have to be based in Canada. | This is an open competition with no set deadline | |
| International | Association for the Advancement of Blood & Biotherapies (AABB) Foundation: Early-Career Scientific Research Grants Program | Up to USD $100,000 for 1 year or 2 years. | These grants are for early-stage investigator-initiated original research in all aspects of blood banking, transfusion medicine and biotherapies. An early-stage investigator is a new investigator who has completed a terminal research degree or medical residency – whichever date is later – within 10 years of the grant application deadline and has not yet been awarded a substantial research grant. | December 1, 2024. | |
| International | Association for the Advancement of Blood & Biotherapies (AABB) Foundation: Process Development Grant | Up to USD $100,000 for 1 year. | This supports improvements to business operations through the development, implementation, and outcomes analysis of innovative processes, techniques or technologies. Proposals that offer potential for widespread dissemination and adoption for the field will receive priority. | December 1, 2024. | |
| International | Cancer Research Institute (CRI): Clinic and Laboratory Integration Program (CLIP) Grant | Up to USD $150,000 per year for 2 years. | This supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CRI CLIP Grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. | LOI: December 1, 2024; Full Application (by invitation): March 1, 2024. | |
| International | Cancer Research Institute (CRI): Clinical Innovator Grant | Up to USD $1M for each clinical trial. Payment will be structured into milestones to ensure that studies will advance and be brought to completion | Innovative immunotherapy clinical trials proposed by academic researchers are vitally important to improving patient outcomes. This will support novel clinical studies that address areas of high unmet need in cancer and seek mechanistic insights into clinical response with a goal of predictive biomarker discovery. To maximize the impact of each clinical trial, CRI will advise on selected studies in a coordinated effort to optimize clinical trial design and translational studies. | Protocol Concept: December 1, 2024; Full Proposal (by invitation): May 1, 2024. | |
| International | American Association for Thoracic Surgery (AATS): Various Opportunities | -- | The AATS Foundation provides educational and research opportunities for surgeons, fellows, residents, and medical students from around the world to enhance their surgical knowledge and technical skills and advance innovation in thoracic and cardiovascular surgery. | December 2, 2024. | |
| International | American College of Gastroenterology (ACG) - Clinical Research Awards: | USD $50,000 for one year. | This will support innovative patient-oriented research with direct applicability to clinical care. | December 2, 2024. | |
| International | American College of Gastroenterology (ACG) - Clinical Research Award Pilot Projects: | USD $15,000 for one year. | This will support innovative patient-oriented research and encourage clinical research among trainees and junior faculty. | December 2, 2024. | |
| International | Paralyzed Veterans of America (PVA) Education Foundation Grants | Ranges between up to USD $10,000 to USD $75,000, depending on the topic category. All grants are for 12 months. | This funds educational projects that benefit and serve individuals with SCI/D, their families and caregivers. There are six topic categories for funding consideration, which are: Consumer, Caregiver, and Community Education; Professional Development and Education; Research Utilization and Dissemination; Assistive Technology; Consumer Guides; and Conferences and Symposia | December 2, 2024. | |
| International | Plastic Surgery Foundation Grants Program: Aesthetic Plastic Surgery Research Grant | Up to USD $25,000 for one year. | This intended to support plastic surgeons in pursuing research in aesthetic/cosmetic plastic surgery. The goals of the research may range from pilot projects to collect preliminary data to support larger future grant proposals, up to more advanced research questions that may lead to findings and results to have a more immediate impact on patient care. | December 2, 2024. | |
| International | Plastic Surgery Foundation Grants Program: Combined Pilot Research Grants | Up to USD $10,000 for one year. | This for innovative research in hand surgery, academic plastic surgery related to research, peripheral nerve research, microsurgery and stimulating fundamental research in plastic surgery. | December 2, 2024. | |
| International | Plastic Surgery Foundation Grants Program:Directed Research Grant: | Up to USD $50,000 for up to 2 years. | This will support basic, translational, and/or clinical research studies that assess breast implant safety, including local and systemic complications and illnesses related to breast implants. Proposals that examine implant surveillance techniques and imaging are also invited. | December 2, 2024. | |
| International | Plastic Surgery Foundation Grants Program: National Endowment for Plastic Surgery | Up to USD $50,000 for up to 2 years. | This is intended to support research projects which translate clinical or basic science research findings into clinically relevant advancements or tools with a high likelihood of impacting daily practice and patient care within the next few years. | December 2, 2024. | |
| International | Plastic Surgery Foundation Grants Program: Pilot Research Grants | Up to USD $10,000 for one year. | This is intended to support residents and junior faculty in their efforts to address focused research questions, obtain preliminary data to support larger grant proposals in the future and develop a line of research that can be carried forward into an academic career | December 2, 2024. | |
| International | Plastic Surgery Foundation Grants Program: Research Fellowships | Up to USD $50,000 for one year. | This supports investigators from the beginning of their careers, during residency and as they advance to becoming experienced and well-established plastic surgeons. The purpose of this grant is to encourage research and academic career development in plastic surgery. Value: Up to USD $50,000 for one year | December 2, 2024. | |
| International | Cystic Fibrosis Foundation (CFF): Gastrointestinal Manifestations of CF: Basic Science Projects | Up to USD $150,000 per year for up to 3 years. | This is for projects that will improve our understanding of the biological basis for the development and progression of gastrointestinal manifestations in cystic fibrosis as well as to identify potential novel therapeutic strategies to manage and treat them. | December 5, 2024. | |
| International | Cystic Fibrosis Foundation (CCF): Pilot and Feasibility Award | Up to USD $50,000/year up to 2 years. | This supports projects that will develop and test new hypotheses and/or new methods that could eventually contribute to the development of a cure for CF and to support promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. | December 5, 2024 (Fall cycle). | |
| International | Cystic Fibrosis Foundation (CFF): Path to a Cure: Research Grants | Up to USD $150,000 per year for up to 3 years. | This supports research that will accelerate the discovery and development of therapies to restore cystic fibrosis transmembrane conductance regulator (CFTR) function in all patients with cystic fibrosis | December 5, 2024. | |
| International | Cystic Fibrosis Foundation (CCF): Research Grant | Up to USD $150,000/year for up to 3 years. | This is intended to facilitate or enable the development of new information that may contribute to the development of new therapies for CF, especially projects focused on advancing CFTR repair and replacement strategies. Proposals must be hypothesis driven and contain sufficient preliminary data to justify support from the Cystic Fibrosis Foundation. | December 5, 2024 (Fall cycle). | |
| International | Cystic Fibrosis Foundation (CCF): Postdoctoral Research Fellowships | Up to USD $75,000/year for up to 2 years. | This is intended to enable research training in new research areas and methods to advance the scientific knowledge of the applicant and to collect data to enable their transition into an independent research career. | December 5, 2024 (Fall cycle). | |
| International | American Society for Gastrointestinal Endoscopy: ASGE Research Grant | Up to USD $75,000 for up to 2 years | To promote research and innovation in gastrointestinal endoscopy in order to advance patient care and digestive health. | December 6, 2024. | |
| International | American Society for Gastrointestinal Endoscopy: ASGE Diversity and Inclusion Research Grant | Up to USD $50,000 for up to 2 years. | To promote studies that advance the field of gastroenterology research and focus on minority health as well as healthcare disparities as it relates to GI disease | December 6, 2024. | |
| International | American Society for Gastrointestinal Endoscopy: ACG/ASGE Epidemiological Research Grant in Gastrointestinal Endoscopy | USD $50,000 for 1 year | Provides support for hghhprojects involving studies on the use and outcomes of gastrointestinal (GI) endoscopy using the GI Quality Improvement Consortium (GIQuIC). For this opportunity, The candidate is required to be an ACG or ASGE member at the time of application and be a physician or clinical researcher (MD, DO, or PhD). | December 6, 2024. | |
| International | Leukemia & Lymphoma Society - Specialized Center of Research (SCOR) grant program | Up to $5M USD for 5 years. | The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. A major emphasis in the SCOR grant program is on clinical translation of scientific results. Ideally, a SCOR application will propose a combination of basic and translational laboratory research that will lead to eventual clinical translation. There should be clear and direct “bench to bedside” translational trajectory from one or more of the Projects in the SCOR. It is important to note that the inclusion of a clinical trial in and of itself may not satisfy this requirement. | LOI: December 6, 2024. Full Application: March 31, 2025. | |
| International | American Brain Tumor Association (ABTA): Discovery Grant | USD $50,000 per year for 1 year. | This is for high risk, high impact research with the potential to change current diagnostic or treatment models. Grants are intended to provide seed-funding for early-stage faculty-level researchers to develop their new ideas, and to get the preliminary data needed to apply for larger grants. To be eligible for ABTA grants, at the start of the grant term, the lead PI must hold a full-time faculty position and cannot have been in a faculty position for more than ten years at the start of the grant term. | LOI: December 11, 2024. Full Application (by invitation): March 27, 2025. | |
| International | American Society of Breast Surgeons Foundation (ASBrS) Grant Funding Program: Various Opportunities | -- | The ASBrS continues its mission to improve the standard of care for breast disease patients through its grant funding program. Each year the Foundation awards grants for research projects and grants related to patient breast care and patient education. Three grant categories are available: Education, Community Outreach, Research. Education, Community Outreach, and Research Grant applications are not limited to American Society of Breast Surgery (ASBrS) members. | December 11, 2024. | |
| International | ResMed Foundation: Physician and Public Awareness | USD $10,000. | These grants are to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. | December 15, 2024. | |
| International | Society of Women in Urology (SWIU): Elisabeth Pickett Research Award | USD $10,000. | This makes funds available for small research grants for basic, translation or clinical urologic research. The awards may be used to continue or supplement a current project or to initiate new study. Applicant must be members of Society of Women in Urology, Inc. | December 15, 2024. | |
| International | AHNS/AAO-HNSF Translational Innovator Award: | USD $100,000 for 2 years. | This award is to support contemporary basic or clinical research focused on neoplastic disease by full time academic head and neck surgeons; to promote novel translational research preferably with biomarker ideas. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS/AAO-HNSF Young Investigator Research Development Award | USD $50,000 for 2 years. | This award is to support a collaborative AHNS/AAO-HNSF research project by fostering the development of contemporary basic or clinical research skills focused on neoplastic disease of the head and neck among new full-time academic head and neck surgeons. The award is intended as a preliminary step in clinical investigator career development and is expected to facilitate the recipient’s preparation of a more comprehensive individualized research plan suitable for submission to the National Institutes of Health or comparable funding agency. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AAO-HNSF Bobby R. Alford Endowed Research Grant | USD $30,000 for 1 year. | Proposed projects should be related to any area of otolaryngology-head and neck surgery and must have direct or potential clinical significance for patients seen by otolaryngologist-head and neck surgeons. Basic science, translational, and clinical research projects may be funded. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AAO-HNSF Maureen Hannley Research Grant | USD $30,000 for 1 year. | The AAO-HNSF wishes to support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research by helping to develop independent research skills and gain experience in advanced methods and approaches needed to become an independent investigator conducting patient-oriented research. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AAO-HNSF Resident Research Grant | USD $10,000 for 1 year. | The purpose of the AAO-HNSF Resident Research Grants are to stimulate original resident research in otolaryngology projects that are well-conceived and scientifically valid, with the potential to advance otolaryngology. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | GSK Research Grant: Social Determinants of Health, Diversity/Equity/Inclusion, and the intersection of patient care with workforce culture | USD $25,000 for 1 year. | This Funding Opportunities Announcement (FOA) invites researchers to conduct studies focused on patient care and workforce culture related to social determinants of health (SDOH) and diversity, equity, and inclusion (DEI). Proposed projects may address diagnosis and treatment models, pre- and post-operative care, the influence of social status and demographics on care, culturally sensitive communication, and the impact of biases. Reviewers will also consider other submissions that address SDOH and/or DEI outside these specified areas. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS/AAO-HNSF Translational Innovator Award | USD $100,000 for 2 years. | The purpose of this award is to support contemporary basic or clinical research focused on neoplastic disease by full time academic head and neck surgeons; to promote novel translational research preferably with biomarker ideas. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS/AAO-HNSF Young Investigator Research Development Award | $50,000 for 2 years. | The purpose of this award is to support a collaborative AHNS/AAO-HNSF research project by fostering the development of contemporary basic or clinical research skills focused on neoplastic disease of the head and neck among new full-time academic head and neck surgeons. The award is intended as a preliminary step in clinical investigator career development and is expected to facilitate the recipient’s preparation of a more comprehensive individualized research plan suitable for submission to the National Institutes of Health or comparable funding agency. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS Alando J. Ballantyne Resident Research Pilot Grant | USD $20,000 for 1 year. | The purpose of this award is to support basic, translational, or clinical research projects in head and neck oncology. Clinical or translational research studies are strongly encouraged and should be specifically related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neck neoplastic disease. The Alando J. Ballantyne Resident Research Pilot Grant memorializes Alando J. Ballantyne, M.D., a giving teacher, dedicated surgeon, and a devoted husband and father | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS Pilot Grant | USD $20,000 for 1 year. | The purpose of this award is to support basic, translational, or clinical research projects in head and neck oncology. Clinical or translational research studies are strongly encouraged and should be specifically related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neck neoplastic disease. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS Presidential Award: Novel Therapeutic Targets and Combinations in Head and Neck Cancer | USD $10,000 for 1 year. | The purpose of this award is to support research projects that seek to identify novel therapeutic targets and combinations in head and neck cancer. Proposed studies may utilize genomics, immune profiling, mechanistic approaches, human tissues (preferred) and/or animal models to identify novel therapeutic targets in the tumor or microenvironment, based on biological dependencies | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS Presidential Award: Understanding Treatment Resistance in Head and Neck Cancer | USD $10,000 for 1 year. | The purpose of this award is to support research projects that seek to understand mechanisms underlying resistance to therapy in head and neck cancer. Any study in head and neck cancer that utilizes genomics, immune profiling, mechanistic approaches, or animal models to understand how such mechanisms might develop and how we might predict the presence/absence of resistance phenotypes prior to treatment is eligible for this award | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | AHNS Thyroid Cancer Survivors’ Association Award for Thyroid Cancer Research | USD $10,000 for 1 year. | The purpose of this award is to support basic, translational, or clinical research projects that further the mission of the Endocrine Section of the American Head and Neck Society. Projects should be specifically related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of thyroid cancer | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | ARS New Investigator Research Grant | USD $40,000 for 2 years. Number available based on merit of applications received. | The purpose of this award is to support basic, translational, or clinical research projects in rhinology.Any member of the American Rhinologic Society who has completed residency and has not received previous, significant outside funding is eligible. The applicant must have, as a mentor, an established researcher who will provide a letter of support stating the extent of involvement in the project and provide a summary of his/her/their research experience. Applications submitted by ineligible PIs will NOT be reviewed by the CORE Study Section. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | ARS Friends in Research Award | USD $25,000 for 2 years. Number available based on merit of applications received. | The purpose of this award is to support basic, translational, or clinical research projects in rhinology.Any member of the American Rhinologic Society who has completed residency and has not received previous, significant outside funding is eligible. Both early and mid-career investigators are encouraged to apply. Applications submitted by ineligible PIs will NOT be reviewed by the CORE Study Section. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | ARS Women in Rhinology Research Grant Sponsored by Medtronic | USD $25,000 for 1 year. | The purpose of this award is to support basic, translational, clinical, health services, or outcomes research projects in rhinology.Any member of the American Rhinologic Society who has completed residency is eligible. In order to be considered, the applicant must be the Principal Investigator (PI) assigned to the application, and the proposed research must include at least one female investigator as either the Principal Investigator or a co-investigator. Applications submitted by ineligible PIs will NOT be reviewed by the CORE Study Section. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | ASPO Research Career Development Award | USD $40,000, one to two years. | The purpose of this award is to provide support for the research career development of otolaryngologists head and neck surgeons who have made a commitment to focus their research endeavors on research oriented to pediatric otolaryngology (e.g. patient-oriented clinical trials, health services, outcomes research, translational research, basic science). | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | ASPO Research Grant | USD $20,000 for 1 year. | The American Society of Pediatric Otolaryngology (ASPO) awards funds annually to support innovative research in pediatric otolaryngology. Researchers (MD, PhD, DMD) in disciplines who will conduct research directly relevant to pediatric otolaryngology are eligible to apply. | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | ASPO Dustin Micah Harper Recurrent Respiratory Papillomatosis (RRP) Research Grant | USD $10,000 for 1 year. | The purpose of this award is to support basic, translational, or clinical research projects in recurrent respiratory papillomatosis (RRP). Clinical or translational research studies are strongly encouraged and should be specifically related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of RRP disease | LOI: December 16, 2024. Applications: January 15, 2025. | |
| International | Cooley’s Anemia Foundation: Clinical Trials in Thalassemia Cell and Gene Therapy | Up to USD $150,000 for up to 2 years. | This seeks to support clinical trials in Cell and Gene Therapy to advance a cure for thalassemia. Both phase I (safety) and phase II (efficacy) trials are eligible for support. | LOI: December 16, 2024. Full Application: February 3, 2025. | |
| International | Emily’s Entourage: Translational Grant Program | USD $100,000 for 2 years. | This opportunity provides critical seed funding to innovative investigators with promising strategies that accelerate research and drug development for those in the final 10% of the cystic fibrosis (CF) community who do not benefit from CFTR modulators, including those with rare and nonsense mutations. The objective of this initiative is to fund promising therapies and drug-delivery mechanisms that have the potential to accelerate the development of gene-based therapies for people with CF. | December 20, 2024. | |
| International | Society of Nuclear Medicine and Molecular Imaging: Mitzi & William Blahd, MD, Pilot Research Grant | USD $25,000 for 1 year. | The pilot research grant is designed to help a basic or clinical scientist in the early stages of their career conduct research that may lead to further funding. Applicant must be no more than five years post training (most recent training; training includes residency, MD/PhD training, professional school, graduate school, post doc, or fellowship). | January 2, 2025. | |
| International | Intuitive Foundation Clinical Research Grants for Robotic-Assisted Surgery | Up to USD $75,000 per project. | These grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes | LOI: January 6, 2025. Full Proposal (by invitation): April 7, 2025. | |
| International | International Association for the Study of Lung Cancer (IASLC): IASLC Young Investigator Grant: | USD $50,000 for 1-year projects | This funds the training of early-career researchers who wish to pursue careers in lung cancer diagnosis, treatment, or laboratory research as well as other aspects of the study of lung tumors. Applications must be within the scope of the following funding priorities to be considered: the etiology, epidemiology, prevention, diagnosis, treatment, and all other aspects of lung cancer and thoracic malignancies. The applicant (MD, DO, PhD, PharmD, or equivalent) must be within five years of initial faculty appointment | January 8, 2025 | |
| International | International Association for the Study of Lung Cancer (IASLC): LCFA/IASLC Translational Research Grants in Thoracic Oncology | USD $100,000 per year for up to 2 years. | The objective of this program is to support research, undertaken by early-career investigators, that aims to improve the care and treatment of individuals with lung cancers and other thoracic malignancies. Eligibility: At the time of application, eligible candidates must be a member of the IASLC. For physicians, be within seven years of completion of residency fellowship. For laboratory scientists, be within seven years of completion of post-doctoral work. | January 8, 2025. | |
| International | International Foundation for Functional Gastrointestinal Disorders: Preceptorship Award | USD $5,000. | This is for junior faculty focused on research in the area of gastrointestinal disorders to visit an internationally recognized research institution for the period of four weeks. | January 12, 2025. | |
| International | International Foundation for Functional Gastrointestinal Disorders: Travel Awards | USD $2,000. | This supports young investigators who have a record of research interest and accomplishment in neurogastroenterology and, especially, in the basic mechanisms or clinical aspects of functional gastrointestinal (GI) and motility disorders | January 12, 2025. | |
| International | International Foundation for Functional Gastrointestinal Disorders: Research Grants | USD $40,000. | This is seeking proposals for research that will ultimately lead to improvements in the understanding of gastrointestinal disorders, its pathophysiology, and the care of patients. | January 12, 2025. | |
| International | International Society for Heart and Lung Transplantation: Ventricular assist device (VAD) coordinator career development grant | Up to USD $20,000. | This aims to further the VAD coordinator’s understanding of care of VAD patients in both the inpatient and outpatient setting from referral through post VAD outpatient care, resource utilization, and patient or caregiver adjustment to life with a VAD and outcomes with the goal of enhancing patient/caregiver decision making and improving the VAD experience, patient survival, and patient and caregiver quality of life. | January 21, 2025. | |
| International | International Society for Heart and Lung Transplantation: Utilization of non-invasive biomarkers in combination with artificial intelligence (AI) or machine learning (ML) in the care of heart transplant | Up to USD $40,000. | This is to fund research utilizing the support of AI and ML in addition to non-invasive biomarkers to optimize evaluation and selection of heart transplant candidates or to augment clinical assessment and management of heart transplant recipients. | January 21, 2025. | |
| International | International Society for Heart and Lung Transplantation: Non-invasive biomarker study using AI or ML analysis in lung transplantation grant | Up to USD $40,000. | This is to fund research that utilizes the support of AI or ML in addition to non-invasive biomarkers to optimize evaluation and selection of lung transplant candidates or to augment clinical assessment and management of lung transplant recipients. | January 21, 2025. | |
| International | International Society for Heart and Lung Transplantation: Extracorporeal photopheresis (ECP) immunomodulation in thoracic transplantation challenge grant | Up to USD $90,000. | This supports studies involving the fully integrated and validated ECP system that will evaluate the basic and translational science of ECP used in the treatment pathway. | January 21, 2025. | |
| International | Society of General Internal Medicine (SGIM): Mary O’Flaherty Horn Scholars in General Internal Medicine Program Grant: | $30,000/year for 2 years, supplemented by matching funds or support of $30,000/year from the scholar’s institution. | This two-year career development award is for junior clinician-educator to support their academic careers while balancing personal and professional responsibilities. Applicants must desire to work part-time, in a 0.5-0.8 FTE position, and agree to allocate the remaining 0.2-0.5 time for dependent care (children, parents, etc.) and self-care and wellness activities. They should be motivated to develop a scholarly project related to provider engagement and wellness, be engaged in caring for underserved patients, and have two committed mentors to support their scholarly activities and a balanced lifestyle. | Nomination Deadline: January 21, 2025. | |
| International | Wellcome Trust: Climate and Mental Health Award: Uncovering mechanisms between heat and mental health | £1-3M for 3-5 years. | This award will fund projects to advance our understanding of how heat impacts anxiety, depression and psychosis in the most impacted groups globally through biological, psychological and/or social mechanisms. Successful applications will propose translational opportunities for climate-resilient solutions and/or mental health interventions. To apply for this award, teams must bring together mental health and climate expertise as well as additional expertise as relevant. Research teams are expected to include relevant lived experience of mental health problems, unless there is a strong justification for not doing so. | January 21, 2025. | |
| International | Radiological Society of North America (RSNA): Research Seed Grant | USD $60,000 for 1 year. | This opportunity gives investigators the chance to define objectives and test hypotheses in preparation for larger grant applications at corporations, foundations and government agencies. The seed data from the projects we fund will give investigators a better idea of feasibility and directionality of research before applying for more funds from other sources. Applicants must be an RSNA member and hold a full-time faculty position in a radiology, radiation oncology or nuclear medicine department at an educational institution. | January 24, 2025. | |
| International | Pfizer RFP: Health Services Research to Improve Management of mestatic Breast Cancer Patients Treated with Tucatinib | USD $250,000 for 18 months. | This will support Investigator Sponsored/General Research proposals that aim to improve therapy management of patients receiving tucatinib in combination with trastuzumab and capecitabine in clinical practice using innovative and community-accessible approaches that may impact patients adherence to treatment, quality of life, or symptom management, and/or facilitate follow-up in daily clinical practice. | January 30, 2025. | |
| International | National League for Nursing (NLN): Nursing Education Research Grants | Up to $30,000 for 1 or 2 years. | This supports high-quality studies that contribute to the development of the science of nursing education. NLN-funded grants promote diversity of research topics and support investigators who demonstrate rigor and innovative approaches to advance the field of nursing education research. Principal investigators must be current NLN members, either through their school or through individual dues payment. | February 4, 2025. | |
| International | National League for Nursing (NLN): Edmund J.Y. Pajarillo Health Informatics and Innovation Collaborative Research Award | USD $2,500. | This supports a PhD doctoral dissertation, DNP research or capstone, or a Master of Science in Nursing student focusing on health informatics and innovation in research in nursing education. Proposed studies must be clearly focused on health informatics and innovation research in nursing education. Preference will be given to NLN members. | February 4, 2025. | |
| International | American Psychological Foundation (APF): Alice F. Chang Cancer Wellness Grant | USD $16,500. | This will support research and research-based projects to improve the lives of cancer patients and/or cancer survivors through psychology. Applicants must be early career psychologists no more than 10 years post-doctoral. | February 7, 2025. | |
| International | Foundation for Food and Agriculture Research (FFAR): Sustainable Food Systems Initiative - Focus on Food | USD $50,000 for 2 years. | The Danone Institute of North America (DINA) Sustainable Food Systems Initiative supports community-based initiatives focused on food as medicine, health and agriculture. Over the two-year grant period, grantees will design, implement and evaluate actionable community-based projects for sustainable food systems that improve human health and nutrition. | February 14, 2025. | |
| International | Society for Vascular Surgery (SVS) Clinical Research Seed Grant | USD $25,000 for 1 year. | This program aims to foster clinical research among SVS members, especially junior members or those new to the Principal Investigator role, by supporting pilot projects with potential for larger funding. Eligible PIs must be SVS members within their first 10 years of practice, or Early Active Members who are board-eligible vascular surgeons with a full-time faculty position and an SVS Active Member mentor. | March 1, 2025. | |
| International | American Psychological Foundation (APF): Visionary Grants | Up to USD $20,000. | The APF Visionary Grants seek to seed innovation through supporting research, education and intervention projects and programs that use psychology to solve social problems in a number of priority areas. Applicants must be graduate students or early career psychologists (no more than 10 years postdoctoral). | April 3, 2025. | |
| International | American Psychological Foundation (APF): Walter Katkovsky Research Grants | Up to USD $22,500. | These support research on the general topic of psychotherapy. Applicants must be be psychologists up to 12 years of postdoctoral. | April 17, 2025. | |
| International | American Psychological Foundation (APF): John and Polly Sparks Early Career Grant for Psychologists Investigating Serious Emotional Disturbance (SED) | Up to USD $22,500. | This supports supports early career psychologists conducting research in the area of early intervention and treatment for serious emotional disturbance in children. Applicants must be early career psychologists (no more than 10 years postdoctoral with a degree from an accredited university). | April 24, 2025. | |
| International | Horizon Europe: EIC Pathfinder Open | Up to EUR 3 million. | This call supports projects in any field of science, technology or application without predefined thematic priorities. | May 21, 2025. | |
| International | American Psychological Foundation (APF): Wayne F. Placek Grants | Up to USD $15,000 | This encourages research to increase the general public’s understanding of homosexuality and sexual orientation, and to alleviate the stress that LGBTQIA+ individuals experience in this and future civilizations | June 12, 2025. | |
| International | American Psychological Foundation (APF): The Springfield Research Fund Grants | Up to USD $21,000 | The Springfield Research Fund Grant supports research of contemporary LGBTQIA+ issues in an effort to dispel stereotypes and other negative information that leads to prejudice and discrimination. Applicants must be early career psychologists no more than 10 years postdoctoral. | June 12, 2025. | |
| International | American Association for Cancer Research (AACR): Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grant, in partnership with Pelotonia & AACR | USD$700,000 for 3 years. | This is intended to fund innovative research projects in breast and gynecologic cancers and to invest in female scientists at the Associate Professor level domestically and globally to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of these cancers with the goal of eliminating cancer health disparities and improving patient outcomes. Proposed projects may be in basic, translational, clinical, or population sciences. | LOI: June 23, 2025. Full application (by invitation only): April 24, 2025. | |
| International | Brain Tumor Charity: Quest for cures - collaborative discovery teams | Up to £1.5 million for over 5 years | This seeks innovative approaches to address the critical questions that could present a paradigm shift for brain tumour research or use unexplored paths to allow for new discoveries to be made. The scheme aims to bring benefits to patients faster by acknowledging the importance of interdisciplinary team approaches in accelerating the understanding and translation of discoveries. | LOI: June 25, 2025. Full application: December 3, 2025 | |
| International | American Psychological Foundation (APF): Marian R. Stuart Grant | USD $20,000 | This will further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicants must be early career psychologists no more than 10 years postdoctoral. | July 10, 2025. | |
| International | Thrasher Research Fund: E.W. “AI” Thrasher Award | Up to USD $550,000 for up to 3 years. | This programs funds projects that are changing pediatric clinical care. Each award is a novel approach to problems plaguing pediatrics. The award is open to applications focusing on any disease or topic within the umbrella of pediatrics, both in and outside the United States. Projects with a shorter distance to clinical applicability are given priority. Hypothesis-driven research is critical. Exploratory or hypothesis-generating research will not be competitive. | Concept Paper: January 14, 2025; July 15, 2025. Full proposal (by invitation only): April 17, 2025; October 30, 2025. | |
| International | American Psychological Foundation (APF): Division 39 Marsha D. McCary Fund Grant for Psychoanalysis | USD $12,000. | This was established to increase public awareness of the benefits of psychoanalytic principles and treatments, and the applicability of psychoanalytic thought to clinical, organizational, and social problems. | August 31, 2025. | |
| International | American Psychological Foundation (APF): Scott and Paul Pearsall Grant | USD $10,000. | This supports graduate and early career work that seeks to increase the public’s understanding of the psychological pain and stigma experienced by adults living with visible physical disabilities, such as cerebral palsy. | October 2, 2025. | |
| International | American Psychological Foundation (APF): John and Polly Sparks Grant for Rural First-Responders Mental Health Interventions: | USD $34,000. | This will will fund the research of psychologists for evidence-based research and intervention in providing mental health training dissemination to first responders in rural areas. Applicants must be early career psychologists no more than 10 years postdoctoral. | October 23, 2025. | |
| International | Horizon Europe: EIC Pathfinder Challenges | Up to EUR 4 million | This supports new, cutting-edge directions in science and technology to disrupt a field and a market or create new opportunities by realising innovative technological solutions to selected challenges. | October 29, 2025. | |
| International | Focused Ultrasound Foundation (FUSF): Research Awards | USD $100,000 for 1 year. | This funds projects involving the use of non-invasive image-guided focused ultrasound to treat disease, including preclinical translational research studies and clinical trials. Funding is prioritized for research in the fields of oncology and neurodegenerative disease. | Continuous. | |
| International | AbbVie Inc.: Investigator-Initiated Study (IIS) Program | -- | This opportunity will support investigator-initiated research that promotes the advancement of medical and scientific knowledge involving AbbVie’s products and therapeutic areas of interest. The research has the capability to expand understanding of AbbVie’s products and their potential applications. Plus, data from IIS research can inform patient care and spark new ideas for further disease-related research. | Continuous. | |
| International | Gateway for Cancer Research: Various Opportunities | Typically in the $200,000 to $1.5 million range for 2-5 years | Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. Gateway funds treatment-based studies at the bedside, including all types of cancers. Research areas include Biomarkers (prognostic or predictive with supportive treatment), Gene Therapy, Basket Trials, Immunotherapy, and Targeted Therapies. | Rolling deadlines 3x per year. Anticipated deadlines for 2024: July or August, and November or December. | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY24 Defense Medical Research and Development Program (DMRDP): Psychedelic Treatment Research Clinical Trial Award | USD $4.9M total costs for 3 years. | Applications submitted to the FY24 DMRDP must propose clinical trials with eligible U.S. Service Members to evaluate treatments for posttraumatic stress disorder (PTSD) and/or traumatic brain injury (TBI) involving the use of covered psychedelic substances. Covered psychedelic substances include: 3,4-Methylenedioxy-methamphetamine (commonly known as MDMA); psilocybin; ibogaine; 5-Methoxy-N,N-dimethyltryptamine (commonly known as 5-MeO-DMT); plant-based alternative therapies. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - Emerging Research Award | Research Level 1: Up to USD $700,000 for up to 3 years; Research Level 2: Up to USD $1.5M for up to 4 years. | Advances research in emerging topics in in traumatic brain injury and/or psychological health, with a unique set of topic areas aligned with TBIPHRP goals (see website for details). | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD)Pre-Announcement: Congressionally Directed Research Programs (CDMRP): FY24 Peer Reviewed Cancer Research Program (PRCRP) - Multiple Opportunities | USD $400,000 - $20,000,000 (check opportunities for amounts) | The FY24 PRCRP will provide funds for research into cancers not addressed in the other CDMRP cancer programs. To be considered for funding, applications for the FY24 PRCRP must address at least one of the FY24 PRCRP Topic Areas. The FY24 PRCRP requires all applications to answer at least one of the Military Health Focus Areas listed on the opportunity website. | Deadlines will be available when the announcments are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Academy of Kidney cancer Scholars Leadership Award | Up to USD $1,500,000 for up to 5 years. | Supports established kidney cancer researchers with a record of mentoring junior faculty level kidney cancer scientists and/or clinicians. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Academy of Kidney Cancer Scholars Early-Career Scholar Award | Up to USD $725,000 for up to 4 years. | Applicant must be within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline. Preliminary data required. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Clinical Trial Award | Up to USD $1,500,000 for up to 4 years. | Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase 1, pilot Phase 2) to test interventions that will have a major impact in the field of kidney cancer. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Concept Award | Up to USD $100,000 for up to 1 year. | Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. Funding for clinical trials is not allowed. Preliminary data are not allowed and should not be discussed. Blinded review. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Idea Development Award | Up to USD $800,000 for up to 4 years; Partnering PI Option: Up to USD $1,200,000 for up to 4 years. | Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved outcomes. Preliminary data are required. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Translational Research Partnership Award | Up to USD $800,000 for up to 3 years. | Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. | Deadlines will be available when the announcements are released | |
| International | Pre-announcement: United States Department of Defense (DoD): Alcohol and Substance Use Disorders Research Program (ASUDRP) | Estimated maximum funding of $3,525,000 for total costs (direct plus indirect costs) | This is to support research of exceptional scientific merit in the area of alcohol, opioid and other substance use disorders research, including opioid use disorder, particularly when co-occurring with PTSD, TBI and/or other mental health conditions. With the goals to treat alcohol and other substance use disorders, and to improve treatment adherence, prevent relapse and reduce risk of misuse, the applications submitted to the FY24 ASUDRP must address the following focus areas: New medication targets; Novel medications; Re-purposed medications; Vaccines and other immunotherapies; Drug-drug combinations; and More potent, longer-acting formulations to counteract opioid (including fentanyl and its analogs) overdose | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY25 Peer Reviewed Alzheimer’s Research Program (PRARP): Transforming Care Award | Up to USD $1.6M total costs or up to USD $1.8M total costs with Career Initiation or Transition (CIT) Option for up to 4 years. | Supports person-centered research that prioritizes both the individual with AD/ADRD and their care partner(s). “Care” does not include medical care (such as medical interventions administered by a physician). | TBA. | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY25 Peer Reviewed Alzheimer’s Research Program (PRARP): Transforming Diagnosis Award | Up to USD $1.5M total costs or up to USD 1.7M total costs with the CIT Option for up to 4 years. | Supports research to reduce barriers and improve diagnosis and prognosis of dementia of AD/ADRD following military service and/or TBI. There is no requirement for studies to be performed in a Veteran or military cohort. | TBA. | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY25 Peer Reviewed Alzheimer’s Research Program (PRARP): Transforming Research Award | Up to USD $1.0M total costs for up to 3 years. | Research must address the priority area of "Reduce risk and prevent AD/ADRD." Clinical trials are not supported, but studies with prospective human subjects' enrollment may be allowed. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Breakthrough Award Funding Level 1 | Funding Level 1: Up to USD $540,000 direct costs or up to USD $900,000 direct costs with the Partnering PI Option for up to 3 years. ; Funding Level 2: Up to USD $1.0M or up to USD $1.5M for up to 3 years; Funding Level 2 – Population Science and Prevention Studies with Partnering PI Option: Up to USD $2.0M for up to 4 years. | Innovative, high-risk/high-reward research that is in the earliest stages of idea development, or an untested theory that addresses an important problem. Proof of concept is the anticipated outcome. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Breakthrough Award Funding Level 2 | Up to USD $1.2M directs costs; up to USD $1.8M direct costs with the Partnering PI Option for up to 3 years; Funding Level 2 – Population Science and Prevention Studies with Partnering PI Option: Up to USD $1.8M directs costs; up to USD $2.4M direct costs with the Partnering PI Option for up to 4 years. | Research that is already supported by substantial preliminary or published data in breast cancer and strongly validates clinical translation in a well-defined context within the breast cancer landscape. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Breakthrough Award Funding Level 3 | Up to USD $4M direct costs or up to USD $5 with the Partnering PI Option for up to 4 years. | Advanced translational studies with a high degree of project readiness. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Breakthrough Award Funding Level 4 | Clinical Trial: $15M direct costs for 4 years; Planning Phase Option: USD $500,000 direct costs for 1 year. | Large-scale projects, including comparative effectiveness trials, that will transform and revolutionize the clinical management and/or prevention of breast cancer. Clinical trials are required. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Era of Hope Scholar Award | Up to USD $3.5M direct costs for up to 4 years. | Supports exceptionally talented, early-career scientists who are independent, non-mentored investigators within six years of their last training position as of the application submission deadline (excluding time spent on family medical leave). | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Clinical Research Extension Award | Up to USD $5M direct costs or up to USD $6.0M direct costs with the Partnering PI Option for up to 4 years. | Supports research that extends or expands the data collection, follow-up, and analysis of breast cancer clinical research studies. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Transformative Breast Cancer Consortium Award | Up to USD $25M direct costs for up to 4 years. | Supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. The consortium should have at least four, but no more than five, project teams, each investigating different projects under a central hypothesis. | TBA. | |
| International | Pre-Announcement US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY25 Breast Cancer Research Program (BCRP): Transformative Breast Cancer Consortium Development Award | Up to USD $100,000 direct costs for up to 1 year. | Provides the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support the application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). | TBA. | |
| International | King Salman Center for Disability Research (KSCDR): Research Grants | Small projects: SAR $100,000; Medium projects: SAR $500,000; Large projects: Unrestricted. | These support projects into the diagnosis and classification of disability, early-intervention, inclusion of the disabled in education, healthcare, training and employment, and the social, economic and psychological effects of disability. | Rolling. | |
| International | Jeffrey Modell Foundation: Specifc Defect Research Program | up to USD $50,000 for 2 years | Supports research that studies the mechanisms and presentation of specific defects of the immune system to gain a better understanding of the defects and their impact on overall health outcomes. | Applications are accepted and reviewed on a rolling basis, so you may apply at any time. | |
| International | Jeffrey Modell Foundation: C.H.I.L.D.R.E.N!® | up to USD $25,000 for 2 years | Supports research focused on children living with PI throughout the world, while addressing healthcare disparities, especially in developing countries, through education, testing, diagnosis, and treatment. | Applications are accepted and reviewed on a rolling basis, so you may apply at any time. | |
| International | American Psychoanalytic Association (APsaA) Fund for Psychoanalytic Research: Research Grant | USD $20,000 for 1 year. | The funds are dedicated to the support of psychoanalytic research and scholarship, while nuturing the development of psychoanalytic investigators. | May 1 and December 31 of each year. | |
| International | AlloSource: Investigator Initiated Research (IIR) Grant Program | Grant requests may include project funding and/or implantable tissue. | AlloSource is working closely with physicians and scientists across multiple orthopedic therapies to continuously improve and bring new allografts to the market, while simultaneously maximizing the gift of donation. | Rolling Deadline | |
| International | Solving Kids' Cancer Therapeutic Development Initiative (TDI) | $50,000 to $500,000 USD for up to 2 years. | Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. | Preliminary Proposal Deadline: Rolling | |
| International | Össur Orthopaedic Research Grant Program | -- | This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics. | Rolling Deadline | |
| International | Aesculap Implant Systems Investigator-Initiated Study Program (IIS) | Dependent on the type of research and availability of support. | This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics. | Continuous | |
| International | Bausch + Lomb Grants | -- | Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. | Rolling Deadlines. Allow 6-12 weeks for proposal review and decision. | |
| International | Horizon Europe Pillar II: Global Challenges and European Industrial Competitiveness | Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines. | Canadian researchers can now apply for and receive funding directly from this program. Pillar II funding is organised into 6 clusters (i.e., themes), including Cluster 1: Health. A consortium of at least three partners is needed to apply: at least one must be from an EU country and two must be from different EU or associated countries (e.g., Canada). | Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines. | |
| NIH | NIH Parent Announcements | -- | This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases. | https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm | |
| NIH | NIH Notice of Special Interest (NOSI): The Role of the Immune System in Aging Brain and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) | -- | This aims at a better understanding of brain immune surveillance and the generation of CNS-directed immune responses in neurodegenerative disorders, specifically the role of cross-talk between innate and adaptive immunity in AD/ADRD onset and progression. The goal is to shed light on the etiology of the immune imbalance (e.g., between peripheral adaptive and brain innate immune responses) typical of neurodegenerative disorders, with promising implications for therapy. These studies may ultimately help with AD/ADRD diagnostics, risk stratification, and discovery of immunotherapeutics. | This notice applies to due dates on or after November 12, 2024, and subsequent receipt dates through December 31, 2027. | |
| NIH | NIH: Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional) | Up to $750,000 in direct costs per year for up to 5 years | This is to support applications to understand the critical drivers of tuberculosis (TB) transmission at the individual and population levels in high-burden settings; to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors; and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission and detect infectious TB. | December 04, 2024. | |
| NIH | NIH: Strategies for Eliminating HIV Proteins: R01 | -- | The purpose of this funding opportunity is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies. This stream will support applications which are hypothesis driven and supported by preliminary data. | December 04, 2024. | |
| NIH | NIH: Strategies for Eliminating HIV Proteins: R21: | Up to USD $275,000 for up to 2 years. | The purpose of this funding opportunity is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies. | December 04, 2024. | |
| NIH | NIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | -- | This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). | December 7, 2024. | |
| NIH | NIH: Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional) | -- | This is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology, as well as social media as a platform for facilitating the identification of adolescents with or at risk for mental illness, for encouraging appropriate mental health service use, and for delivering preventive and therapeutic interventions. | January 28, 2025; October 20, 2025. | |
| NIH | NIH Co-infection and Cancer (R01 Clinical Trial Not Allowed) | -- | This is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment. | February 5, 2025; June 5, 2025; October 5, 2025. | |
| NIH | NIH Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) | -- | The National Institute of Aging (NIA) and NIMH intends to support applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both bio behavioral and neurobiological pathways leading to NPS. | Standard due dates apply on or after February 5, 2025 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | Standard due dates apply on or after February 5, 2025 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) | -- | This NOFO)invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. | Standard due dates apply on or after February 5, 2025 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Notice of Funding Opportunity (NOFO)- HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional) | -- | This aims to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on ‘Whole Person Health’ and enhancing pain treatment and management strategies towards personalized pain medicine. To be considered responsive to this NOFO, applications should focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding the biological mechanisms and/or psychosocial aspects of pain occurring with: use of pain therapy/management; a second pain condition; a comorbid health condition; a cormorbid mental health condition; opioid use/misuse; alcohol use/misue; or substance use/misuse. | February 06, 2025. | |
| NIH | NIH Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) | -- | This encourages research grant applications to develop in vitro, ex vivo or in vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. In the R33 phase, both small molecule and biologic (such as peptides, proteins, oligonucleotides, etc.) screening efforts are supported. R61 activities include (but are not limited to) set up and optimization, standardization, and validation of measures of fundamental cellular/molecular events such as binding, bioactivity at the target, and activity downstream of the target relevant to neurological function | February 18, 2025; June 18, 2025; October 20, 2025; February 18, 2026; June 18, 2026; October 20, 2026; February 18, 2027; June 18, 2027; October 20, 2027. | |
| NIH | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | -- | This provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the National Institute of Neurological Disorders and Stroke (NINDS) mission. Therapeutic agents include small molecules or biologics. | February 18, 2025; June 18, 2025; October 20, 2025; February 18, 2026; June 18, 2026; October 20, 2026; February 18, 2027; June 18, 2027; October 20, 2027 | |
| NIH | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) | -- | This encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Models proposed for this would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention. | February 18, 2025; June 18, 2025; October 20, 2025; February 18, 2026; June 18, 2026; October 20, 2026; February 18, 2027; June 18, 2027; October 20, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research | -- | This is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. | This notice applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024. | |
| NIH | NIH R21: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) | -- | The purpose of this is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) | -- | This opportunity seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aligns with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). | This notice applies to due dates on or after May 7, 2024, and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH: Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) | -- | This opportunity encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed) | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21. | This notice applies to subsequent recipt dates through January 8, 2025. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope. | This notice applies to subsequent recipt dates through January 8, 2025. | |
| NIH | NIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest | -- | This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals. | This notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed) | -- | To stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism. | Standard dates apply until January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders (R21 Clinical Trials Not Allowed) | -- | To stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics. | Standard dates apply until January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research | -- | National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. | This Notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research | -- | This is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease (AD) and Alzheimer's disease-related dementias (ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). | January 08, 2025. | |
| NIH | NIH: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | -- | This is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies among underrepresented communities or that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. | This notice for new applications applies to due dates on or after September 07, 2024 and subsequent receipt dates for new or resubmission applications through February 05, 2025. | |
| NIH | NIH: Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, misuse, and dependence. The term "behavioral treatment" includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches | February 5, 2025. | |
| NIH | NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. | This notice applies to due dates on or after February 8, 2024 and subsequent receipt dates through February 10, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through February 16, 2025. | |
| NIH | NIH: Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses: R01 - Clinical Trial Optional | The purpose of this funding opportunity is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement. Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. This will support projects with a maximum duration of 5 years. | This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through October 5, 2025. | ||
| NIH | NIH: Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses: R21 - Clinical Trial OptionalNIH: | The purpose of this funding opportunity is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement. Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged.This will support shorter term (up to two years) developmental and/or exploratory research activities | This notice applies to due dates on or after February 16, 2025 and subsequent receipt dates through October 16, 2025. | ||
| NIH | NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) | -- | The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through February 19, 2025. | |
| NIH | NIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) | -- | This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. | February 20, 2024; August 19, 2024; February 19, 2025. | |
| NIH | NIH: Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R33 Clinical Trial Optional) | -- | This opportunity addresses a crucial research gap regarding approaches to understanding and enhancing relationships individuals with a substance use disorder (SUD) have with their loved ones. Family, loved ones, and support persons play a critical role in the recovery process and are a critical element of the recovery capital of an individual with a SUD. This NOFO seeks phased (R61/R33) studies that address the role of support persons and loved ones in six focal areas: (1) developing interventions to enhance the well-being and coping skills among support persons; (2) enhancing knowledge of effective interventions for SUDs and reducing stigma, negative attitudes, and misconceptions among support persons; (3) testing enhancements to existing evidence-based interventions and practices to include engagement of support persons; (4) developing new interventions or adapting existing interventions to leverage support persons as lay interventionists; (5) developing and testing care navigation interventions and resources, particularly during care transitions; and (6) dyadic approaches to support engagement in evidence-based care when both parties have experienced or are experiencing a SUD. | February 27, 2025. | |
| NIH | NIH Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) | -- | This seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps. | This notice applies to due dates on or after July 29, 2024 and subsequent receipt dates through February 28, 2025. | |
| NIH | NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | -- | This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation. | March 15, 2024; March 14, 2025. | |
| NIH | NIH: Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01 Clinical Trial Not Allowed) | -- | The purpose of this funding opportunity is to support multidisciplinary research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections. | March 26, 2025. | |
| NIH | NIH Tobacco Regulatory Science (R01 Clinical Trial Optional) | -- | This is to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). | This notice applies to due dates on or after May 6, 2024 and subsequent receipt dates through May 2, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis | -- | The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health. Applicants are required to measure and report results using a standard THC unit in all applicable human subjects research. | This notice applies to subsequent receipt dates through May 5, 2025. | |
| NIH | NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | -- | This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | -- | This notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. While there has been signficant progress identiying and intervening on risk and protective factors for substnce use, population-level impact of substance use prevention interventions has not yet been achieved. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening | -- | This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | -- | This encourages applications proposting to test multilevel strategies and interventions to improve the update of evidence-based screening services across the lifespan and in populations including, but not limited to those experiencing health disparties and those that are underserved. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH National Eye Institute (NEI) Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | -- | The goal is to stimulate the use of exisiting human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tool, ethods that hev the potential for significant impact in areas relevant to the NEI mission. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH National Eye Institute (NEI) Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | -- | This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. This supports applicants in their planning efforts to conduct collaborative clinical research. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | This notice applies to subsequent receipt dates though May 8, 2025. | |
| NIH | NIH BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) | -- | This opportunity seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. Preliminary feasibility data are not required, and it is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research | June 2, 2025; January 20, 2026. | |
| NIH | NIH BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | -- | This opportunity seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. It is expected that the proposed technologies and approaches have previously demonstrated their transformative potential through initial proof-of-concept testing, and are ready for accelerated refinement through iterative engineering and end-user feedback, appropriate for a path towards sustainable dissemination and user-friendly incorporation into routine neuroscience research. | June 2, 2025; January 20, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Application of Artificial Intelligence in Treatment Development for Substance Use Disorders | -- | The purpose of this NOSI is to elicit projects that would leverage the power of generative artificial intelligence/machine learning algorithms (AI/ML) and predictive models to accelerate medication discovery and development for treatment of SUDs while reducing the risk of failure. Areas of Interest: • De novo design of new synthesizable molecules targeting addiction circuitry using AI tools • Identification of medications that can be repurposed for treatment of SUDs • Optimization of promising compounds for SUD treatment • AI-enabled virtual screening of medication candidates • Chemical synthesis design for the most effective synthetic route and ease of manufacturing • Intelligent neuromodulation protocols guided by AI/ML methods • Combinatorial approaches designed through computational modeling • Implementation of AI/ML algorithms to augment existing digital and sensor-based technologies • AI/ML-based software as a medical device (SaMD) to support recovery, prevent relapse and improve treatment outcomes | This notice applies to due dates on or after June 5, 2025 and subsequent receipt dates through September 8, 2028. | |
| NIH | NIH Mutiple-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | -- | This supports applicatins to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effeciveness, pragmatic and/or implementation research clinical trials. The objective it to present the scientific rationale for the clinical trial and a comprehensive scientific and operation plan that describes it. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) | -- | This supports applicatins to develop and implement a Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effeciveness, pragmatic and/or implementation research clinical trials. The objective is to present a comprehensive plan to provide overall project coordination, administration, data management and biostatistical support for the clinical trial proposed. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | -- | This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | -- | This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This does not support research on basica cancer biology, late-stage clinical trials, risk assessment studies, epidemiological studies or studies of behavioral interventions. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 12, 2025. | |
| NIH | NIH: Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | -- | This intends to support preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. | February 13, 2025; June 12, 2025. | |
| NIH | NIH Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | -- | Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 16, 2025. | |
| NIH | NIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | -- | This supports efforts to optimize and evaluate pharmacodynamic (PD) measures the neurophysiological processes that are disrupted within or acoss mental disorders in both healthy humans and in another species relevant to the therapuetic development pipeline. This initative will support inital proof of concent studies aimed at identifying meaures for potential development as preclinical assas for evaluating potential new drug and device therapies and their targets. | This notice applies to due dates on or after February 21, 2024 and subsequent receipt dates through June 20, 2025. | |
| NIH | NIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | -- | This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used there in. The goal is to improve the translational application of animal models and/or outcome measures for the development of non-addicitve analgesics. | This notice applies to due dates on or after October 18, 2022 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | -- | This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. | This notice applies to due dates on or after February 27, 2024 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy | -- | This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or co-morbidities that predispose patients to COVID-19-Associated Coagulopathy (CAC) are also of interest. | This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through July 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations | -- | This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. | This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) | -- | This is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. | August 2, 2024; August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations | -- | This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. | This notice applies to subsequent receipt dates through August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) | -- | This NOSI supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV in people with Substance Use Disorders (SUD). | This notice applies to due dates on or after July 15, 2023 and subsequent receipt dates through August 15, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | -- | This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations or 3-D multi-cellular in vitro systems of human lung cells and will employ state-of-art multi-omics measures. | This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities | -- | This notice is to solicit projects on preventive interventions that address cardiometabolic risk factors across the lifespan in populations that experience health disparities. | This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | -- | This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. | This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment | -- | This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams. | This notice applies to subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information | -- | This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making. | This notice applies to subsequent receipt dates through September 24, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes | -- | This notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into healthcare settings. It is to encourage intervention research focused on addressing exposure to violence to improve individual-level health processes and outcomes. | This notice applies to subsequent receipt dates through October 5, 2025. | |
| NIH | NIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | -- | This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | -- | This invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to the National Institute on Aging (NIA)'s research mission. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIH NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | -- | This supports small research projects on cancer that can be carried out in a short period of time with limited resources. | This notice applies to due dates on or after February 22, 2024 and subsequent receipt dates through October 17, 2025. | |
| NIH | NIH HEAL Initative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed) | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH HEAL Initative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed) | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data | -- | This notice is to highlight its interest in recieving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets. This invites research grant applications that propose innovative state-of-the-art methods and generalizable approaches to address problems with large health data sets or analytic tools. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Research Opportunities Centering the Health of Women Across the HIV Research Continuum | -- | The NIH Office of Research on Women’s Health (ORWH) and Office of AIDS Research (OAR), in partnership with our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving HIV research and training grant applications that explicitly and intersectionally center the health needs of cisgender women and girls, and gender-diverse people. Despite tremendous scientific advances that have translated to substantial progress in confronting the HIV epidemic, women – and particularly women of color, young women and girls, and transgender women – and gender-diverse individuals remain disproportionately affected by HIV. | This notice applies to due dates on or after June 20, 2024 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Impact of Policy Interventions Aimed at Addressing Social Determinants of Health to Improve Functioning and Well-being for People with Serious Mental Illnesses | -- | This will fund research on the impact of social and economic policy interventions that address social determinants of health (SDOH) on improvements in access and engagement with mental health treatment, mental health functioning, and quality of life for people with serious mental illnesses, with special attention to understanding the underlying mediators/change mechanisms of those policies on outcomes. | This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and care Continuum Outcomes (R34 Clinical Trials Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | -- | Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through January 13, 2026. | |
| NIH | NIH BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) | -- | Seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. | This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026. | |
| NIH | NIH BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | -- | This seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. | This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | -- | National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior | -- | The notice encourages collaborations between computtionally and experimentally focused investigators. It seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations after cognitive, affective, or social processing in humans or animals | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) | -- | This invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. This notice will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signatur. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH: SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This opportunity encourages applications for multi-center clinical trials focused on neurological emergencies (excluding stroke). The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. | This notice applies to due dates on or after June 10, 2024 and subsequent receipt dates through February 6, 2026. | |
| NIH | NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This encourages applications for multi-center clinical trials focused on neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. | This notice applies to due dates on or after February 6, 2024 and subsequent receipt dates through February 6, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): School Mental Health: Innovative Approaches to Expand Access to Evidence-Based Interventions and Services | -- | This notice is to outline priorities for school-based intervention and services research and encourages applications that incorporate: (1) end-user/community-engaged approaches with systematic attention to challenges related to gaining access to schools, competing demands/workload issues, workforce shortages, and privacy concerns; (2) research-practice partnerships that leverage existing practice infrastructure (3) plans to quantify the resources necessary to implement the intervention, tool, or strategy; and (4) strategies that promote health equity. | This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through March 17, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | -- | This notice will support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through May 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | -- | This notice is to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related, geographic, cultural considerations, and health disparities influence the types of care that are provided. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through May 8, 2025. | |
| NIH | NIH NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) | -- | This encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the National Institute of Allergy and Infectious Diseases (NIAID). | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through May 13, 2026. | |
| NIH | NIH Secondary Analysis and Integration of Exisiting Data to Eludicate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Secondary Analysis and Integration of Exisiting Data to eludicate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R01 clinical Trial Not Allowed) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R21 clinical Trials Not Allowed) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026. | |
| NIH | NIH BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21 Clinical Trial Not Allowed) | -- | This seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation. | This notice applies to due dates on or after June 18, 2024 and subsequent receipt dates through June 15, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatement (R01 Clinical Trial Optional) | -- | Studies proposed should identify and validate new neuromodulation targets and provide a comprehensive understanding of the behavioral and neurobiological effects of stimulation to these targets and their constituent brain networks. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatement (R01 Basic Experiemental Studies wth Humans Required) | -- | For studies that meet both the definition of basic research and the NIH definition of a clinical trial. Types of studies that should submit include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disoders Treatement (R61/R33 Clinical Trial Optional) | -- | Supports applications that are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional) | -- | This seeks to support dissemination and implementation (D&I) research proposals leveraging well-established cohorts of people living with HIV (PLWH) to increase the acceptability, feasibility, implementation, scale-up, scale-out, and sustainability of evidence-based interventions (EBIs) that target comorbid conditions and diseases. This NOSI hopes to promote new or existing collaborative efforts between observational, interventional, and D&I scientists, which is a crucial next step to ensure maximal public health impact of clinical trial and cohort studies. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment | -- | This notice solicits applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment | -- | This notice solicits theoretically- and empirically-driven research applications which will: 1) advance measurements and understanding of HIV-related ISD or intersectional social-structural factors to examine the mechanisms and pathways by which they are barriers to HIV prevention and HIV treatment; 2) develop and test interventions to address their impact to improve HIV prevention and HIV treatment outcomes; or 3) conduct implementation science research of evidence-based interventions. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH R21: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | -- | This notice is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). | This notice applies to due dates on or after October 16, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on HIV-associated Malignancies | -- | This notice calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of malignancies, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) | -- | This notice is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. It is to seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH Notice of Funding (NOFO) - Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) | -- | This seeks to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH: National Cancer Institute's (NCI) Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | -- | The NCI is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the Division of Cancer Treatment and Diagnosis (DCTD), and Office of HIV and AIDS Malignancies (OHAM). | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | -- | This supports investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH BRAIN Initiative: Brain-Behavior Quantification and Synchronization Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trial Optional) | -- | This seeks applications that bring together transdisciplinary teams and aim to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution objective measurement of behavior at the organismal level, with synchronous capture of dynamic environmental data; 2) develop advanced analytic approaches to integrate multidimensional behavioral, neural and environmental data; and 3) develop and test new theoretical and computational models aiming to advance understanding of behavior as a complex dynamic system. | October 9, 2024; October 9, 2025; October 9, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities | -- | This notice is intended to support the use of the telehealth interventions and tools aimed at the prevention, management and treatment of heart, lung, blood, and sleep conditions, and of cancer in rural communities. The purpose of this notice is to provider-to-provider telehealth (PPT) is defined broadly to include any health technology meant to connect healthcare providers to one another for the care of patients. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through October 9, 2026. | |
| NIH | NIH Prevention and Intervention approaches for Fetal Alcohol Spectrum Disorders (FASD) (R61/R33 Clinical Trial Optional) | -- | This is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disoders (FASD) (R34 Clinical Trial Optional) | -- | This R34 planning grant applications focuses on prevention and intervention strategies for FASD throughout the lifespan. The intent is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI): Small Research Grant (R03 Clinical Trial Optional) | -- | This is for research that examines the ELSI of human genetic or genomic research. Applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. | This notice applies to due dates on or after February 19, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI):Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | -- | This is for studies of the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI):Research (R01 Clinical Trial Optional) | -- | This is for applications that propose to study the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026. | |
| NIH | NIH: Notice of Special Interest (NOSI): Development of Organotypic Culture Models for Transplantation Immunology Research | -- | This notice encourages applications that focus on the development and validation of tissue-, stem-, or progenitor-cell-derived “3D” organotypic culture models (OCM) for transplantation immunology research. This will support applications that focus on development of allogeneic or xenogeneic OCM to study immunologic features of transplant-related diseases or conditions. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through November 16, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | -- | This encourages R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026. | |
| NIH | NIH: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | -- | The purpose of this opportunity is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. | This notice applies to due dates on or after March 26, 2024, and subsequent receipt dates through November 19, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Existing and Accessible Datasets for Implementation Research Strategies and Testing - LEAD FIRST | -- | This notice promotes the use of existing and accessible datasets to inform community-engaged dissemination and implementation (D&I) research on heart, lung, blood and sleep conditions to advance health equity. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH: Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) | -- | This notice is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives (1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and (2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Core Mission Areas | -- | This will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community. | This notice applies to due dates on or after June 16, 2023 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Data Science Research in HIV: Responding to a Dynamic, Complex, and Evolving HIV Epidemic with Artificial Intelligence/Machine Learning | -- | This seeks to advance data science research in HIV by encouraging the generation of cutting-edge synthetic datasets, artificial intelligence, and machine learning approaches to expand our capacity to address the dynamic, complex, and evolving HIV epidemic. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia | -- | This is to encourage research on task-based behavioral measures that engage brain systems relevant to anhedonia. These behavioral measures are expected to be used as a proxy for brain target engagement, therefore neuroimaging or other brain measures with similar spatial resolution should be used to demonstrate that the proposed behavioral tasks engage brain systems relevant to anhedonia. | This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | -- | This notice is to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 10, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | -- | This is to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. Research proposed in response to this NOSI should be generalizable, comprehensive, high-throughput and genome-scale. | This notice applies to due dates on or after September 5, 2024 and subsequent receipt dates through January 10, 2027. | |
| NIH | NIH: NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) | -- | This notice encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. | This notice applies to due dates on or after May 13, 2024 and subsequent receipt dates through January 13, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Fundamental Mechanisms and Functions of Co-transmission in the Brain | -- | This notice encourages basic neuroscience research in animals to investigate the fundamental mechanisms and functions of co-transmission (i.e., release of multiple neurotransmitters by one neuron) that support brain activity and behavior. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 4, 2027. | |
| NIH | NIH: New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through February 5, 2027. | |
| NIH | NIH: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) | -- | This is to support high priority research at the intersection of HIV and substance use. This NOFO invites research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. | This notice for new applications applies to due dates on or after January 11, 2024 and subsequent receipt dates for new or resubmission applications through February 11, 2027. | |
| NIH | NIH: New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. | This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through February 16, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) | This notice is to encourage applications which are focused on development of diagnostics, therapeutics, and vaccines for herpes simplex virus (HSV). The NIH Strategic Plan for HSV Research focuses on four strategic priorities: HSV virology basic research, better HSV diagnostics, strategies to address HSV treatment and cure, and research to prevent HSV infection. This NOSI focuses on furthering the development of new products for prevention of HSV infection, as well as improving the diagnosis and treatment of patients living with herpes, addressing three of these four strategic priorities. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through April 5, 2027. | ||
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach. | This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through May 7, 2027. | |
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through May 7, 2027 | |
| NIH | NIH Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances | -- | This notice calls for research to build a body of evidence on how to implement and sustain OEND in HIV prevention and care settings. Research should develop and test models for integrating OEND; examine barriers and facilitators to successful implementation; and develop implementation strategies to address provider, organizational, structural, reimbursement and other factors impacting implementation. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through May 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Neuromodulatory Control of Circuits Underlying Mental Health Relevant Behaviors | -- | This notice solicits applications seeking to understand how neuromodulatory signals dynamically control and coordinate neural circuit responses in real-time during complex mental health relevant behaviors including cognitive, social, and affective functions. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through May 10, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health | -- | This calls for research grant applications that address adherence to recommended treatment and prevention regimens or maintenance of behaviors to promote positive health outcomes (collectively referred to as health behaviors). Applications may address health behavior initiation, execution, and/or persistence through mechanistic studies, efficacy trials, or implementation research. Descriptive studies and intervention research may address relevant determinants at one or more levels of ecologic influence, including the individual, caregiver/family, provider, healthcare system, and community levels. Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged. | This notice applies to due dates on or after July 15, 2024 and subsequent receipt dates through July 14, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI) Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research | -- | The purpose of this NOSI is to demonstrate NIAID’s interest in research to continue validating the utility of CC mouse lines to 1) more faithfully reproduce human immune responses and advance our understanding of the host genetics involved in immune regulation/function and 2) to select and evaluate CC and CC-RIX mouse lines suitable for specific studies and disease models within research areas of interest to NIAID. | This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through July 16, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases | -- | This is to encourage innovative research on the role of DEAD/H-box helicases in immune homeostasis and activation/function at steady state and in response to immune-mediated or infectious diseases. | This notice applies to due dates on or after October 5, 2024, and subsequent receipt dates through July 16, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment | -- | This notice is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. Understanding the heterogeneity of obesity is necessary for precision and targeted implementation of obesity prevention and treatment interventions. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Supporting Research Using the Resources from the Osteoarthritis Initiative (OAI) | -- | This is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute on Aging (NIA) are interested in receiving research grant applications that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data, and images. | This notice applies to due dates on or after October 5, 2024, and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Systems Modeling of Infection and Immunity Across Biological Scales | -- | This is to advance computational modeling approaches and technologies focused on infectious, allergic, and/or immune-mediated diseases across different biological scales. Projects will also have the opportunity to collaborate with the NIAID CoE for Systems Modeling of Infection and Immunity across Biological Scales. | This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH: Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | -- | This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years. | This notice applies to due dates on or after January 28, 2025 and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Women’s Health Research | -- | This notice is to highlight interest in receiving research applications focused on diseases and health conditions that predominantly affect women (e.g., autoimmune diseases; depressive disorders, Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD), gender-based-violence), present and progress differently in women (e.g., cardiovascular disease; HIV; reproductive aging and its implications), or are female-specific (e.g., uterine fibroids; endometriosis; menopause). | This NOSI applies to due dates on or after May 6, 2024, and subsequent receipt dates through November 4, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Developing and Testing Multi-level Physical Activity Interventions to Improve Health and Well-Being | -- | This notice is to increase and maintain health-enhancing physical activity in a wide range of population groups, including populations that experience health disparities, children, older adults, and persons at risk for mental/behavioral health conditions, and any subpopulations that can be characterized by the intersection of two or more of these descriptors. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through November 14, 2027. | |
| NIH | NIH NOSI: Research on Illicit Drug Markets | -- | This is to encourage research that examines illicit drug markets and informs prevention, intervention, treatment, and harm reduction efforts. Applications are strongly encouraged to consider who the end-users of the research findings will be (e.g., policy-makers, prevention scientists, local health departments, etc.), and if/when appropriate, include possible end-users in the research team to ensure that the knowledge generated will have real-world impact. | This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through September 8, 2028. | |
| NIH | NIH: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | -- | This invites research grant applications that will identify, develop, and/or test strategies to disseminate and implement evidence-based interventions into public health, clinical practice, and community (e.g., workplace, school, place of worship) settings. Studies that promote equitable dissemination and implementation of evidence-based interventions are encouraged. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. | This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through October 5, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Model-informed Drug Development (MIDD) Approaches to Facilitate the Development of Therapeutics for Substance Use Disorders | -- | This NOSI encourages, but is not limited to, research applications that use MIDD approaches to: Predict drug toxicology profile, pharmacokinetics; Assist in pre-formulation studies, formulation design and optimization; Optimize clinical trial design; Support efficacy extrapolation in a new patient population; and Develop precision medicines or personalized treatment plans for special patient sub-populations. | This notice applies to due dates on or after June 5, 2025 and subsequent receipt dates through September 8, 2028. | |
| NIH | NIH: Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | -- | This seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This is intended to support the development of digital health test beds that leverage well-established digital health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through October 5, 2027. | |
| NIH | NIH: Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) | -- | This seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. | This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through October 5, 2027. | |
| NIH | NIH: National Institute on Aging Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | -- | This funding opportunity invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. The goals are to encourage biomedical, social, and behavioral research and research training directed toward greater understanding of the aging process and the diseases, special problems, and needs of people as they age. | This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIH: Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | -- | This funding opportunity encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science. | This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through October 5, 2027. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Planning Grant Program | -- | This intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Two funding mechanisms are available: R34 Clinical Trials Optional and U34 Clinical Trials Optional. | This notice applies to due dates on or after February 25, 2025 and subsequent receipt dates through October 25, 2027. | |
| NIH | NIH NOFO: Imaging – Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) | -- | This NOFO encourages Small Research Grant (R03) applications to facilitate the entry of investigators (both newly independent and established investigators) to the area of development and application of novel molecular tools and methods of neuroimaging for substance use disorder (SUD) and addiction research. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources | Mulitple dates in 2025 through 2028. |
